Final Data from Phase 2 Expansion Study of NUC-7738 Remains on Track for 2026 Advancing Additional Indications and Combination Strategies for NUC-7738 Cash Runway Expected to Extend into 2029 EDINBURGH, United Kingdom, Aug. 13, 2026 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) (“NuCana” or the
EDINBURGH, United Kingdom, June 01, 2026 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) (“NuCana” or the “Company”), a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer, announced the appointment of Ian Webster as Chief Financial
Final Data from Phase 2 Expansion Study of NUC-7738 Expected in 2026 NUC-7738 Receives FDA IND Clearance: Planned Initial Studies to Focus on Melanoma Advancing Additional Indications and Combination Strategies Cash Runway Expected to Extend into 2029 EDINBURGH, United Kingdom, May 14, 2026 (GLOBE
NUC-7738 Demonstrates Clinical Activity and Favorable Safety in Patients with PD-1 Inhibitor-Resistant Melanoma Final Data from Phase 2 Expansion Study of NUC-7738 Expected in 2026 Advancing Additional Indications and Combination Strategies Cash Runway Expected to Extend into 2029 EDINBURGH, United